Search results for "From ACP Journal Club"
In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes
An analysis of recent manufacturer-sponsored studies of finerenone show it to be a potentially important new treatment for patients with type 2 diabetes and albuminuric chronic kidney disease (CKD), although it poses risk for serious hyperkalemia, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/05/13/6.htm
13 May 2022
In type 2 diabetes, SGLT2 inhibitors reduced risk for serious hyperkalemia without increasing hypokalemia
A reduction in hyperkalemia could allow use of angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or aldosterone-receptor blockers in at-risk patients, justifying the prescribing of sodium-glucose cotransporter 2 (SGLT2) inhibitors, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/09/16/6.htm
16 Sep 2022
Review: Adding a DPP-4 inhibitor to an SGLT-2 inhibitor reduces genital, but not genitourinary, tract infections
The authors of an accompanying ACP Journal Club commentary noted that although the risk for bias in the five reviewed studies was reportedly low, the results were imprecise and inconsistent, leaving little confidence in the evidence of an apparent reduction in infection risk with dipeptidyl peptidase-4 (DPP-4) inhibitors.
https://diabetes.acponline.org/archives/2018/04/13/7.htm
13 Apr 2018
KDIGO made 12 recommendations for managing diabetes with CKD
The kidney group's guideline supports metformin and sodium–glucose cotransporter-2 inhibitors as first-line therapies for patients with chronic kidney disease (CKD) based on consistent trial data showing their effectiveness, noted an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2021/03/12/6.htm
12 Mar 2021
In high-risk T1DM, real-time continuous glucose monitoring vs self-monitoring reduced hypoglycemic events
The study provides compelling evidence for clinicians to recommend real-time continuous glucose monitoring to their patients at high risk for severe hypoglycemia, the ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2018/06/08/7.htm
8 Jun 2018
Some glucose-lowering drugs reduce risk for major adverse cardiac events
An umbrella review found cardiovascular benefits from sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, but an ACP Journal Club commentary cautioned that included patients were on a wide array of background treatments.
https://diabetes.acponline.org/archives/2020/08/14/7.htm
14 Aug 2020
Cyclical pressurized topical wound oxygen therapy increased healing of refractory diabetic foot ulcers
An industry-funded randomized trial showed that topical wound oxygen therapy is efficacious, but more data on effectiveness, outcomes, and cost are needed, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/04/10/6.htm
10 Apr 2020
In type 2 diabetes with periodontitis, intensive periodontitis treatment improved glycemic control at 1 year
Putting these findings into practice may require incorporating dental professionals into diabetes care teams and training clinicians who treat patients with diabetes to recognize and assess periodontal disease and make appropriate referrals, the ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2019/05/10/8.htm
10 May 2019
Glargine and liraglutide improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin, while liraglutide reduced CV events vs. glargine, glimepiride, or sitagliptin
Although microvascular complications and death were not materially different among the four treatment groups in a recent trial, the results do allow inferences about the role of sulfonylureas and dipeptidyl peptidase-4 inhibitors in practice, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/01/13/8.htm
13 Jan 2023
In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors
A cohort study's finding of increased risk of diabetic ketoacidosis with sodium-glucose cotransporter-2 (SGLT2) inhibitors is relevant to clinical decision making, but not definitive given the limitations of observational research, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/01/08/6.htm
8 Jan 2021